RECRUITING

An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this clinical study is to determine the effectiveness of the Erchonia® GVS in improving the appearance of skin laxity on the abdominal region.

Official Title

An Evaluation of the Erchonia Corporation GVS Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity on the Abdominal Region

Quick Facts

Study Start:2025-05-30

Study Completion:2026-11-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06941610

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years to 70 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Subject has signed a written informed consent form. * Male or female 22 to 70 years of age, inclusive. * Desire to undergo treatment for skin laxity of the abdomen. * Subject's score on the skin laxity scale for skin on the abdomen is 1 (mild) or 2 (moderate). * Subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in diet, exercise or medication routine during the course of the study. * Subject agrees to refrain from taking any medication(s) or supplements(s), whether prescription or OTC, or undergo any procedures indicated for weight loss, or for fat reduction or improving the appearance of the skin in the abdominal area (e.g. liposuction, ultrasound therapy) for the duration of participation in the clinical study. * Willing to have research photos taken of treatment areas. * Understands, and is able and willing to comply with all study visits, treatments and evaluations schedules and requirements. * Females are at least 9 months post-partum. * Females are post-menopausal, surgically sterilized, or using a medically accepted form of birth control for at least 3 months prior to the study and agree to continue to do so for the duration of study participation.	* Skin laxity resulting from genetic disorders, including but not limited to Ehlers-Danlos Syndrome. * History of undergoing a fat reduction procedure (e.g., liposuction, bariatric surgery, abdominoplasty). * Botulinum toxin or other aesthetic drug injections within the abdomen area within the past 6 months. * History of any major prior surgery in the abdominal area * Implanted medical prostheses (such as clips, pins or plates) in or adjacent to the area of intended treatment. * Active implanted device such as a pacemaker, defibrillator, or drug delivery system. * Any clinical and significant dermatological skin condition(s) in the intended abdominal treatment area, such as skin infections or rashes, extensive scarring, psoriasis, etc.. * Tattoo or former tattoo at the treatment area. * Current moderate to heavy tobacco use, defined as smoking 10 or more cigarettes per day (or equivalent use of other nicotine-containing products such as cigars, pipes, chewing tobacco, or e-cigarettes) within the past 6 months * History of chronic drug or alcohol abuse. * Pregnant or intending to become pregnant in the next 6 months. * Currently enrolled in a clinical study of an unapproved investigational drug or device.

Inclusion Criteria

Exclusion Criteria

* Subject has signed a written informed consent form.
* Male or female 22 to 70 years of age, inclusive.
* Desire to undergo treatment for skin laxity of the abdomen.
* Subject's score on the skin laxity scale for skin on the abdomen is 1 (mild) or 2 (moderate).
* Subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in diet, exercise or medication routine during the course of the study.
* Subject agrees to refrain from taking any medication(s) or supplements(s), whether prescription or OTC, or undergo any procedures indicated for weight loss, or for fat reduction or improving the appearance of the skin in the abdominal area (e.g. liposuction, ultrasound therapy) for the duration of participation in the clinical study.
* Willing to have research photos taken of treatment areas.
* Understands, and is able and willing to comply with all study visits, treatments and evaluations schedules and requirements.
* Females are at least 9 months post-partum.
* Females are post-menopausal, surgically sterilized, or using a medically accepted form of birth control for at least 3 months prior to the study and agree to continue to do so for the duration of study participation.

* Skin laxity resulting from genetic disorders, including but not limited to Ehlers-Danlos Syndrome.
* History of undergoing a fat reduction procedure (e.g., liposuction, bariatric surgery, abdominoplasty).
* Botulinum toxin or other aesthetic drug injections within the abdomen area within the past 6 months.
* History of any major prior surgery in the abdominal area
* Implanted medical prostheses (such as clips, pins or plates) in or adjacent to the area of intended treatment.
* Active implanted device such as a pacemaker, defibrillator, or drug delivery system.
* Any clinical and significant dermatological skin condition(s) in the intended abdominal treatment area, such as skin infections or rashes, extensive scarring, psoriasis, etc..
* Tattoo or former tattoo at the treatment area.
* Current moderate to heavy tobacco use, defined as smoking 10 or more cigarettes per day (or equivalent use of other nicotine-containing products such as cigars, pipes, chewing tobacco, or e-cigarettes) within the past 6 months
* History of chronic drug or alcohol abuse.
* Pregnant or intending to become pregnant in the next 6 months.
* Currently enrolled in a clinical study of an unapproved investigational drug or device.

Contacts and Locations

Study Contact

Travis Sammons

CONTACT

3214731251

tsammons@erchonia.com

Study Locations (Sites)

Cesar A. Lara M.D. Weight Loss & Wellness

Dunedin, Florida, 34698

United States

Collaborators and Investigators

Sponsor: Erchonia Corporation

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-30

Study Completion Date2026-11-01

Study Record Updates

Study Start Date2025-05-30

Study Completion Date2026-11-01

Terms related to this study

Additional Relevant MeSH Terms

Skin Laxity